NCT06810089Completed
Examination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other
Source: ClinicalTrials.gov · Last updated 5 Feb 2025
Brief summary (registry, in English)
The goal of this observational study is to investigate etiology and pathogenesis of nasolacrimal duct obstruction and dacryocystitis in different adult clinic groups. The main question it aims to answer is: Are there differences in terms of staining scores between groups? There are 4 groups: Cohort 1: Primary Nasolacrimal Duct Obstruction without any dacryocystitis history Cohort 2: Primary Nasolacrimal Duct Obstruction with dacryocystitis history Cohort 3:Traumatic Nasolacrimal Duct Obstruction Cohort 4:Nasolacrimal Duct Obstruction with Membranes in the Nasolacrimal Sac
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 78 (actual)
- First submitted
- 30 Jan 2025
- Start date
- 15 May 2023
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- Uludag University
- NCT number
- NCT06810089
What you commit to
- Study type: Observational
- Participants enrolled: 78
- From 15 May 2023 to the primary completion date, 28 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bursa Uludag University, School of Medicine Coordinator of this site? Confirm its status | Bursa | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.